Drug news
Abor Pharma to market Edarbi and Edarbyclor in USA
Takeda Pharmaceutical Company Limited and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC announced that Takeda and Arbor have entered into a license, development and commercialization agreement. It will provide Arbor with exclusive rights to market and sell Edarbi (azilsartan medoxomil) and Edarbyclor (azilsartan medoxomil and chlorthalidone) in the United States market effective September 12, 2013.